Home » Topics » BioWorld Science

BioWorld Science
RSS

Parke-Davis and Xenova begin evaluation of novel antibacterial

Aug. 23, 1996

Repel proved effective in preclinical studies

Aug. 23, 1996

Takeda describes cephem antibacterial agents

Aug. 23, 1996

Genzyme's Seprafilm approved by FDA

Aug. 23, 1996

Kanebo and Ontogen to codevelop cell adhesion factor inhibitor

Aug. 23, 1996

Dusa completes phase IIb for ALA PDT

Aug. 23, 1996

Dyad granted U.S. patent for oligonucleotides

Aug. 23, 1996

More tachykinin NK1 antagonists reported by Sandoz

Aug. 23, 1996

Protein Polymer Technologies and Ethicon sign R&D agreement

Aug. 23, 1996

Coagulation factor X inhibitors described by Yamanouchi

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...